Evaluating the effect of Montelukast on the amount of nasal congestion following orthognathic surgery

The evaluation of oral Montelukast prescription effect on the amount of nasal congestion of patients following orthognathic surgery.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150613022697N12

Enrollment

Registered

2022-07-05

Start date

2022-08-01

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rate of nasal congestion. Acute maxillary sinusitis

Interventions

Intervention 1: Intervention group: One dose of 10 mg oral Montelukast tablet ( made by Abidi pharmaceutical company under the brand name Airokast ) will be dissolved in 10cc of apple juice and will b

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients suffering from skeletal class 3 deformity, requiring advancement of the maxilla and set back of mandible using Lefort 1 and BSSO (Bilateral Sagittal Split Osteotomy ) technique respectively. Patients between 18 to 40 years old. Patients who are categorized in the 1st and 2nd group according to the ASA (American Society of Anesthesiology ) Patients who completed the informed consent.

Exclusion criteria

Exclusion criteria: Patients with a history of sinus diseases, sinus infection, and allergy. Patients with a history of smoking and alcohol. Patients with a history of cleft palate.

Design outcomes

Primary

Measure	Time frame
Rate of nasal congestion in the specified time period. Timepoint: 1 week before and 1 week after the surgery. Method of measurement: Rhinomanometry test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahand Samieerad

Mashhad University of Medical Sciences

samieerads@mums.ac.ir+98 51 3882 9501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026